Search

An analysis of germline DNA in people with advanced cancer finds that inherited mutations may be more common than expected in this group.

… Tuesday, September 5, 2017 Summary An analysis of germline DNA in people with advanced cancer finds that inherited mutations may be more common than expected in this group. The findings have implications for genetic counseling and screening. Memorial Sloan Kettering’s genomic-sequencing test, called

September is Pediatric Cancer Awareness Month and at MSK, we continue to work to advance research to bring about better treatments and awareness to our youngest and most vulnerable patients not only in September, but every day.

… Tuesday, September 1, 2020 When we think about progress in fighting cancer, some of the most hopeful stories over the last few years have involved advances in treating children diagnosed with pediatric cancers. Once uniformly fatal, today, many children are thriving, beating the odds that once were stacked

For the first time, MSK has been named one of Fast Company’s Best Workplaces for Innovators, ranking No. 9 out of 100 on its 2025 list of awardees.

… Tuesday, September 9, 2025 For the first time, MSK has been named one of Fast Company’s  Best Workplaces for Innovators , ranking No. 9 out of 100 on its 2025 list of awardees. Fast Company recognizes companies that excel at fostering creative cultures by encouraging and supporting innovation from employees

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

… Friday, September 30, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Danwei Huangfu, PhD Danwei Huangfu Awarded National Human Genome Research Institute MorPhiC Award Danwei Huangfu, PhD , was named a recipient of the newly created National Human Genome

MSK Kids doctors report advances in treating pediatric cancers at the 2019 meeting of the American Society of Clinical Oncology.

… Monday, June 3, 2019 Summary At the 2019 annual meeting of the American Society of Clinical Oncology, MSK Kids pediatric experts presented updates on the treatment of cancer in children, including encouraging news on targeted therapies and a promising drug-delivery technique for a rare brain tumor. This

Johanna Joyce, of the Sloan Kettering Institute's Cancer Biology and Genetics Program, has been named the first incumbent of a Geoffrey Beene Junior Faculty Chair.

… Sunday, April 1, 2007 Summary Johanna Joyce, of the Sloan Kettering Institute’s Cancer Biology and Genetics Program, has been named the first incumbent of a Geoffrey Beene Junior Faculty Chair. Johanna Joyce, of the Sloan Kettering Institute’s Cancer Biology and Genetics Program , has been named the

Meet Ben Hegel, a senior program coordinator in the Sloan Kettering Institute. “My introduction to Pride in college was through a celebratory lens,” says Ben. “But my relationship to Pride has changed.” He still celebrates, but he points out that the Pride March is just that — a march, not a parade. “It was started by marginalized people who were marching for their rights.”

… Wednesday, June 23, 2021 Ben Hegel is a swimmer. He has loved the water since his boyhood in New Hampshire, where he spent summers jumping off a covered bridge into the local brook with friends — the kind of childhood activity that made his future husband ask him if he grew up in Mayberry, the iconic

Memorial Sloan Kettering Cancer Center (MSK) is accepting applications for the 2025 Cohort of the MSK Innovation Hub (iHub) Challenge program. Digital health companies with innovations leveraging AI to address critical issues in the drug discovery process are encouraged to apply.

… Wednesday, June 4, 2025 Memorial Sloan Kettering Cancer Center (MSK) is accepting applications for the 2025 Cohort of the MSK Innovation Hub (iHub) Challenge program. Digital health companies with innovations leveraging AI to address critical issues in the drug discovery process are encouraged to apply

A new treatment that selectively seeks out prostate cancer cells shows great promise for treating advanced forms of the disease.

… Thursday, June 3, 2021 Update: On March 23, 2022, the US Food and Drug Administration approved 177 Lu-PSMA-617 for prostate cancer that has spread and grown resistant to other drugs. “FDA approval of this therapy will enable even more people who had essentially been given death sentences to survive and

Meet Cesar Figueroa Ortiz, who says, “The mission of MSK really resonated with me, all the employees seemed very happy, and the patients said great things about their care.”

… Wednesday, October 13, 2021 For  Cesar Figueroa Ortiz , New York City is his long-awaited home. As a native of Bogotá, Colombia, he remembers stepping out of a subway station into Times Square several years ago and finding himself surrounded by throngs of people speaking multiple languages. “I had never